Fulvestrant with additional palbociclib in advanced or metastatic HR-positive HER2-negative breast cancer after progression to fulvestrant monotherapy. -FUTURE trial a multicenter study-
Latest Information Update: 15 Jun 2024
At a glance
- Drugs Fulvestrant (Primary) ; Palbociclib (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms FUTURE
- 24 Oct 2023 Results (n=56) assessing efficacy of cell-free DNA (cfDNA) changes on clinical outcomes and biological effects, respectively, after short-term palbociclib and fulvestrant treatment for patients with hormone receptor (HR)-positive and human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer presented at the 48th European Society for Medical Oncology Congress
- 13 Sep 2022 Status changed from recruiting to completed, according to Results presented at the 47th European Society for Medical Oncology Congress.
- 13 Sep 2022 Results assessing efficacy and safety of fulvestrant monotherapy HER2-negative breast cancer, presented at the 47th European Society for Medical Oncology Congress.